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Chronic thromboembolic pulmonary hypertension (CTEPH) is a vascular disease characterized by 
the presence of organized thromboembolic material in pulmonary arteries leading to increased 
vascular resistance, heart failure and death. Dysfunction of endothelial cells is involved in CTEPH. 
The present study describes for the first time the molecular processes underlying endothelial 
dysfunction in the development of the CTEPH. The advanced analytical approach and the protein 
network analyses of patient derived CTEPH endothelial cells allowed the quantitation of 3258 
proteins. The 673 differentially regulated proteins were associated with functional and disease protein 
network modules. The protein network analyses resulted in the characterization of dysregulated 
pathways associated with endothelial dysfunction, such as mitochondrial dysfunction, oxidative 
phosphorylation, sirtuin signaling, inflammatory response, oxidative stress and fatty acid metabolism 
related pathways. In addition, the quantification of advanced oxidation protein products, total 
protein carbonyl content, and intracellular reactive oxygen species resulted increased attesting the 
dysregulation of oxidative stress response. In conclusion this is the first quantitative study to highlight 
the involvement of endothelial dysfunction in CTEPH using patient samples and by network medicine 
approach.
Chronic thromboembolic pulmonary hypertension (CTEPH) is a major complication of pulmonary embolism, 
characterized by an abnormal increase of pulmonary artery pressure due to the presence of organised thrombo-
embolic material in pulmonary arteries that has not resolved after a period of appropriate anticoagulant  therapy1. 
The progressive increase of pulmonary vascular resistance in CTEPH may ultimately lead to right ventricular 
failure and  death1 . CTEPH is a dual vascular disorder, that combines occluded pulmonary vessels and distal 
arteriopathy in non-occluded vessels. Inflammation, autoimmunity, and angiogenesis may also  occur2,3. The 
mechanisms underlying the persistence of thrombotic lesions and distal arteriopathy are poorly understood. The 
vascular endothelium, constituted by a thin layer of endothelial cells (ECs), is at the interface between circulating 
blood and the vessel wall. It regulates homeostasis, platelet activity, leukocyte adhesion and  thrombosis4,5. The 
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endothelium comprises adherents and tight junctions and expresses proteins, such as VE-cadherin in association 
with a-, b-, and g-catenins; platelet endothelial cell adhesion molecule 1 (PECAM-1); cortical actin filaments 
linked with zonula occludens-1 (ZO-1), vinculin and α-actinin, involved in actin filament network. Oxidative 
stress causes phosphorylation and reorganization of occludin and PECAM-1, reduces levels of vascular endothe-
lium catenins and actin-binding proteins, resulting in disruption of the tight and adherent  junctions6.
Endothelial dysfunction plays a fundamental role in promoting thrombus formation and pulmonary vascular 
remodeling. In pathological conditions, the loss of endothelium homeostatic function induces the disorganiza-
tion of the vascular wall and the consequent development of vascular lesions. E-selectin, intercellular adhesion 
molecule (ICAM)–1, tissue factor, and vascular endothelial growth factor (VEGF)  receptors7 are specific markers 
of endothelium dysfunction. In addition Kv channels and the  Ca2+ signal are dysregulated in the development of 
pulmonary vascular remodelling in patients with idiopathic pulmonary arterial hypertension (IPAH)8. Pulmo-
nary endarterectomy (PEA) is the treatment of choice in CTEPH. The intravascular thrombotic material along 
with the adhered fibrotic endothelial layer is surgically removed. As a result, pulmonary hemodynamics improve 
dramatically, with a complete resolution of pulmonary hypertension in most  cases9–11. The location occlusive 
lesions in distal vessels in several patients precludes their surgical removal. In these cases, pharmacological treat-
ment and/or balloon pulmonary angioplasty (BPA) are potential therapeutic  alternatives12.
The physiological mechanisms underlying CTEPH are still unknown and the present study of in depth 
description of patient endothelium’s phenotypes may help to get an early diagnosis and better prognosis of 
CTEPH disease. Label free quantitative proteomics approach and network analysis of differentially regulated 
proteins in patient-derived cells provide a unique opportunity to investigate the molecular mechanisms of the 
disease.
Results
Differentially regulated protein pathways in CTEPH. To characterize the potential molecular mech-
anisms underlying endothelial dysfunction in the development of the CTEPH, patient-derived CTEPH-ECs 
and healthy Human Pulmonary Artery Endothelial Cells (HPAECs) were analyzed by label free quantitative 
proteomics approach. 3258 proteins and 27,678 unique peptides were identified and quantified. 673 proteins 
were differentially regulated of which 82 proteins were overexpressed, and 232 proteins resulted down-regulated 
in the CTEPH-ECs compared to the HPAEs group, with a ratio’s threshold of 1.5 (Fig. 1, Table 1, Suppl. Table 1). 
Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 (PLOD2, ratio = 5.50) and Transgelin (TGLN, ratio = 5.28), 
proteins involved in the cross-linking respectively of collagen and actin, resulted highly overexpressed, indicat-
ing the presence of fibrosis in CTEPH  ECs13,14. 
Endoglin (ENG, ratio = 3.05), a vascular endothelium glycoprotein was upregulated. It is involved in the 
positive regulation of angiogenesis, response to hypoxia, positive regulation of collagen biosynthesis and nega-
tive regulation of nitric-oxide (NO) synthase processes. Nitric oxide synthase 3 was also highly down expressed 
(NOS3, ratio = 0.52) indicating low concentration of NO and consequent impairment of vascular  remodelling15,16 
(Table 1).
Von Willebrand Factor (vWF), an important adhesion protein involved in vascular haemostasis, was down 
regulated (ratio = 0.42), as also validated by RT-PCR analyses (Suppl. Figure 1).
Cell movement and angiogenesis functional modules were predicted to be decreased (p value 7.40  e-05, 44 
genes, z score -2.994), thanks to the contribution of differentially regulated proteins, such as RALA (ratio = 0.52), 
ERAP2 (ratio = 0.17) TPT1 (ratio = 5.20), MCM2 (ratio = 2.11) and CNN2 (ratio = 2.17) (Fig. 2 and Suppl. Fig-
ure 2). The decrease of the calcium signalling pathway (z score –2.23, p-value 2.73  e-3, 9 genes) correlates with 
the decrease of PI3K/AKT, mTOR, NFAT, eiF4 and p70S6K pathways (Fig. 3, Suppl. Table 2). The differentially 
expressed proteins describing the pathways are directly involved in cell proliferation, essential in the remodelling 
of vascular endothelium. The regulation of these proteins, such as integrin or phosphatase activator isoforms, 
disagreed with expression in healthy samples in literature, attesting an overall dysregulation of these pathways 
in CTEPH disease.
Protein network analyses revealed a pronounced mitochondrial dysfunction (p-value 3.10  e-29, 34 genes). 
Figure 4 shows the downregulated respiratory and oxidative phosphorylation pathways in mitochondria. Pro-
teins belonging to complexes I, II and III, such as cytochrome c1 (Cyc1, ratio = 0.64), glutathione peroxidase 
4 (GPX4, ratio = 0.22), NADH ubiquinone oxidoreductase core subunit A8 (NDUFA8, ratio = 0.43) succinate 
dehydrogenase complex flavoprotein A (SDHA, ratio = 0.60) were down expressed. GPX4 is an essential anti-
oxidant peroxidase that protect cells from oxidative damage by preventing membrane lipid peroxidation. How-
ever, in the present study GPX4 showed a drastic downregulation (ratio = 0.2), suggesting the dysregulation of 
oxidative stress/damage response. Interestingly the metabolism of reactive oxygen species resulted decreased 
(z score -0.684, p-value 7.8  e-10, 8 genes) (Fig. 5), showing an impaired response to oxidative stress, confirmed 
by down regulation of NRF2 pathway (z score -1.342, p-value 5.93  e-3, 34 genes), principal actor in preventing 
oxo-damage (Fig. 3, Suppl. Table 2).
mRNA translation was up regulated, as resulted from the increase of EIF2 signaling pathway (p value 1.00 
 e-11, 21 genes, z score 1.941) in which eukaryotic translation initiation factors and ribosomal proteins were over 
expressed. The down regulation of proteins, such as Lysosomal Pro-X carboxypeptidase (PRCP, ratio = 0.26) 
induced a decrease of angiogenesis functional module (z score -0.389, p-value 1.72  e-05) and cell movement of 
leukocytes signaling (z score -1.50, p-value 1.12  e-04), key components of thrombus resolution.
Fatty acid metabolism (z score -0.933, p-value 2.58  e-10, 38 genes) was decreased while the concentration of 
lipids (z score 1.846, p-value 1.74  e-6, 39 genes) was increased, attesting dysfunction in lipid metabolism during 
CTEPH disease (Suppl. Figure 3 and 4). In addition, inflammation of organ was predicted to be increased (z 
score 3.147, p-value 5.03 e -05, 24 genes) (Suppl. Figure 5 and Suppl. Table 3).
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To understand the status of oxidants, the levels of advanced oxidation protein products, (AOPPs), total 
protein carbonyl content (PCO), and intracellular reactive oxygen species (ROS) were quantified. Similarly, to 
study the status of antioxidant levels the GSH (reduced)/GSSG (oxidized) ratio, and NADPH (reduced)/NADP 
(oxidized) ratio was measured. As shown in Fig. 6, the levels of AOPPs, total PCOs, and intracellular ROS were 
increased in dysfunctional ECs of CTEPH, whereas GSH to GSSG and NADPH to NADP ratios were decreased.
Discussion
CTEPH is a multi-factorial disease and its diagnosis and treatment are complex. This study represents the first 
functional analyses of protein network changing during CTEPH, using patient-derived cells. The advanced 
analytical approach in combination with the study of dysregulated pathways allowed the identification of several 
important abnormal regulated functional modules, such as mitochondrial metabolism, cell proliferation signal-
ling, oxo-response and fatty acid metabolism, proving the presence of endothelial dysfunction.
Akt-mTOR pathway has multiple downstream effects, related to different cell and tissue types. In CTEPH 
and related diseases this pathway is activated by thrombin, inducing an enhance of calcium concentration, cell 
proliferation and endothelium  remodelling16. In this study the differentially regulated proteins, such as integrin 
alpha, nitric oxide synthase and protein phosphatase 2, inhibited cell proliferation, showed by the dysregula-
tion of AKT-mTOR, calcium, integrin and NFAT network modules. To date, mTOR has gained wide interest in 
its potential therapeutic role in several proliferative diseases such as cancer. The role of mTOR in pulmonary 
hypertension it is not fully understood. Previous work showed an obvious downregulation of of mTOR in lung 
tissues from patients with pulmonary arterial hypertension (PAH) which was reverted in specific adenovector, 
mTOR overexpressing  mice17. After mTOR rebalance mice showed a marked reduction in right ventricular 
hypertrophy and a reduction of pulmonary artery remodelling. It is not known whether the same phenomena 
could be happening in CTEPH patients. Another work showed that smooth muscle cells and/or myofibroblasts 
isolated from pulmonary endarterectomy specimens presented higher expression levels of PDGF and PDGF 
receptors known to potently activate the Akt/mTOR  pathway18. CTEPH cells increased phosphorylation of Akt, 
which subsequently caused an increase in phosphorylated mTOR and p70S6K and that could be inhibited by 
rapamycin. The levels of mTOR compared to healthy pulmonary artery smooth muscle cells or endothelial cells 
without PDGF stimulation are not clear to confirm the basal levels of mTOR in patients with CTEPH vs control 
Figure 1.  Distribution of altered proteins in CTEPH-ECs cells. In the above scatter plot, X-axis represents log2 
ratio and y-axis represent − log p value of significantly differentially regulated proteins. Green colour symbolizes 
down-regulation, red colour symbolizes upregulation.
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Protein Accession numbers Protein names Gene names log2 (ratio)
O00469 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 PLOD2 2.47
Q5U0D2 Transgelin TAGLN 2.41
A0A0P1J1R0 Translationally-controlled tumor protein TPT1 2.38
P68133 Actin, alpha skeletal muscle; ACTA1 2.23
V9HW83 Retinal dehydrogenase 1 HEL-S-53e 1.71
H0YNW5 Deoxyuridine 5-triphosphate nucleotidohydrolase, mitochondrial DUT 1.40
J3QR09 Ribosomal protein L19; RPL19 1.38
Q5ISS1 ADP-ribosylation factor 1; ARF1 1.34
P68366 Tubulin alpha-4A chain TUBA4A 1.18
Q9UJC5 SH3 domain-binding glutamic acid-rich-like protein 2 SH3BGRL2 1.17
A0A024R222 Phosphoserine aminotransferase PSAT1 1.16
B4DDF4 Calponin; CNN2 1.13
B1AHB1 DNA helicase;DNA replication licensing factor MCM5 MCM5 1.11
B3KXZ4 DNA helicase;DNA replication licensing factor MCM2 MCM2 1.08
Q14566 DNA replication licensing factor MCM6 MCM6 1.05
Q8WX93 Palladin PALLD 1.05
O95433 Activator of 90 kDa heat shock protein ATPase homolog 1 AHSA1 1.05
K7ELC2 40S ribosomal protein S15 RPS15 1.02
Q8NG19 Collagen alpha-1(XVIII) chain;Endostatin COL18A1 -1.00
L7UUZ7 Integrin beta ITGB3 -1.01
A0A0S2Z3L0 Electron transfer flavoprotein subunit alpha, mitochondrial ETFA -1.01
Q53YE7 Amine oxidase [flavin-containing] A MAOA -1.02
B3KNK4 Phosphatidate cytidylyltransferase CDS2 -1.03
Q8WYJ5 Histidine triad nucleotide-binding protein 2, mitochondrial HINT2 -1.03
B4E2S7 Lysosome-associated membrane glycoprotein 2 LAMP2 -1.04
A0A024R8T3 Acyl-coenzyme A oxidase; ACOX1 -1.04
B4DEH0 39S ribosomal protein L10, mitochondrial MRPL10 -1.05
A0A0S2Z5A5 Septin-9 43,352 -1.05
Q96N83 Podocalyxin PODXL -1.06
B4DKM6 Serum paraoxonase/arylesterase 2 PON2 -1.06
A0A024RC61 Aminopeptidase N ANPEP -1.07
P38117 Electron transfer flavoprotein subunit beta ETFB -1.07
A0A096LPI6 ES1 protein homolog, mitochondrial C21orf33 -1.09
Q6DHZ2 cAMP-dependent protein kinase type II-beta regulatory subunit PRKAR2B -1.09
A0A024R9D7 2,4-dienoyl-CoA reductase, mitochondrial DECR1 -1.09
P49006 MARCKS-related protein MARCKSL1 -1.10
Q53FJ5 Prosaposin PSAP -1.10
B4E324 Carboxypeptidase; CTSA -1.10
Q9NV96 Cell cycle control protein 50A TMEM30A -1.10
Q14XT3 Cytochrome c oxidase subunit 2 COX2 -1.11
P35580 Myosin-10 MYH10 -1.11
B7Z8A2 Prenylcysteine oxidase 1 PCYOX1 -1.11
Q96CM8 Acyl-CoA synthetase family member 2, mitochondrial ACSF2 -1.12
Q9Y4D7 Plexin-D1 PLXND1 -1.15
A0A024RAB6 Basement membrane-specific heparan sulfate proteoglycan core protein;Endorepellin;LG3 peptide HSPG2 -1.16
B2R7D2 Multiple inositol polyphosphate phosphatase 1 MINPP1 -1.16
A0A1B0GW44 Cathepsin D; HEL-S-130P -1.17
A0A024RAD8 Delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrial ALDH4A1 -1.17
P16284 Platelet endothelial cell adhesion molecule PECAM1 -1.18
Q9UHL4 Dipeptidyl peptidase 2 DPP7 -1.18
Q8TDB4 Protein MGARP MGARP -1.19
P51970 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 8 NDUFA8 -1.21
Q9BVJ8 Beta-hexosaminidase;Beta-hexosaminidase subunit alpha HEXA -1.21
B4DJQ8 Dipeptidyl peptidase 1; CTSC -1.23
A8K9J6 CD276 antigen CD276 -1.23
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cells. Additionally, Ogawa et al. work significantly differs with the present findings as the cell population isolated 
from the pulmonary endarterectomy specimens is  different18. In the present study only endothelial cells and not 
smooth muscle cells or myofibroblasts were isolated. Despite both cell lines co-exist in pulmonary arteries and 
interact constantly between each other both cells play different roles in vascular homeostasis. This could explain 
why the expression levels of mTOR in endothelial CTEPH cells are different to smooth muscle cells. However, 
this protein functional module can be targeted by drug or an indication for early diagnosis of CTEPH disease 
since its activation allows the remodelling of vascular endothelium.
The quantitative proteomics approach showed for the first time the protein PLOD2 as the most upregulated 
protein attesting its key role in CTEPH. PLOD2 is an attachment site for carbohydrates and it is involved in the 
stability of collagen fibrils. Collagen plays a key role in the maintenance of integrity and elasticity of normal 
vessel walls as well as atherosclerotic vessel walls and it stimulates the thrombosis formation and scar forma-
tion processes particularly in PAH  patients19. Under the hypoxic conditions, PLOD2 mediate the remodelling 
of extracellular matrix in synergy with collagen prolyl hydroxylases (P4HA1 and P4HA2)20. PLOD2 is involved 
in collagen deposition that induces the reduction of vascular  elasticity20. PLOD2 promotes the cross-link of 
collagen, important event for the formation and stabilization of insoluble collagen fibrils. Collagen contain-
ing pyridinoline cross-links are difficult to degrade by collagenases, increasing collagen deposition and tissue 
stiffness. Over-expression of PLOD2 and over-production of insoluble collagen fibres in CTEPH disease could 
increase the collagen ‘s deposition, tissue’s stiffness, myofibroblast’s differentiation and platelet’s  aggregation13,14. 
COL18A1, involved in the maintenance of vessel wall integrity and structure in  atherogenesis20,21, was down regu-
lated. On the other hand, TAGLN showed an extensive upregulation with a ratio of 5.3 in CTEPH-ECs. Recent 
study has shown that TAGLN overexpression promoted the proliferation and migration of human pulmonary 
Protein Accession numbers Protein names Gene names log2 (ratio)
O75923 Dysferlin DYSF -1.25
P04275 von Willebrand factor;von Willebrand antigen 2 VWF -1.26
P49407 Beta-arrestin-1 ARRB1 -1.27
Q9Y2Q5 Ragulator complex protein LAMTOR2 LAMTOR2 -1.28
Q6IB89 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 7 NDUFA7 -1.29
Q9NSC5 Homer protein homolog 3 HOMER3 -1.31
Q53H18 Beta-galactosidase GLB1 -1.32
A0A0C4DFN8 NADPH:adrenodoxin oxidoreductase, mitochondrial FDXR -1.34
A8K335 Gamma-glutamyl hydrolase GGH -1.34
A0A140VJL0 3-hydroxyisobutyryl-CoA hydrolase, mitochondrial HIBCH -1.35
A0A024R8Q1 Lysosomal alpha-glucosidase; GAA -1.36
B3KQQ0 Peptidyl-prolyl cis–trans isomerase FKBP9 FKBP9 -1.39
A0A090N7X0 GTPase IMAP family member 4 HIMAP4 -1.39
Q5URX0 Beta-hexosaminidase; HEXB -1.41
P36551 Oxygen-dependent coproporphyrinogen-III oxidase, mitochondrial CPOX -1.41
A0A024RA75 3-hydroxyisobutyrate dehydrogenase HIBADH -1.42
B4DTT0 N-acetylglucosamine-6-sulfatase DKFZp686E12166 -1.44
A0A090N8H2 GTPase IMAP family member 8 hIAN6 -1.45
Q7Z7M4 Superoxide dismutase; SOD2 -1.47
Q92626 Peroxidasin homolog PXDN -1.48
Q14165 Malectin MLEC -1.52
B4DSE2 Tripeptidyl-peptidase 1 TPP1 -1.53
P04040 Catalase CAT -1.55
Q96DI8 Heme oxygenase 1 HMOX1 -1.55
B4DJI2 Granulins; GRN -1.56
Q5TBU5 Adipogenesis regulatory factor hCG_1773630 -1.58
P30837 Aldehyde dehydrogenase X, mitochondrial ALDH1B1 -1.58
Q5NKV8 Intercellular adhesion molecule 1 ICAM1 -1.59
A0A024R5L0 Lysosomal Pro-X carboxypeptidase PRCP -1.91
Q8NHP8 Putative phospholipase B-like 2; PLBD2 -2.01
A0A090N8Z4 GTPase IMAP family member 1 IMAP1 -2.04
K7ERP4 Glutathione peroxidase; GPX4 -2.18
A0A024RDG9 3-hydroxybutyrate dehydrogenase type 2 BDH2 -2.21
B2R769 Endoplasmic reticulum aminopeptidase 2 ERAP2 -2.53
V9HW74 Ubiquitin carboxyl-terminal hydrolase; HEL-117 -3.17
Table 1.  List of protein differentially regulated in CTEPH patients versus controls.
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arterial smooth muscle cells (PASMC), strengthened cytoskeleton; suppression of this protein activated PASMC 
apoptosis, reducing cell proliferation and  migration22. The higher expression of TAGLN might be related to the 
hyperproliferative phenotype of CTEPH-ECs and it might have an important role in endothelial dysfunction. Fur-
thermore, a drastic alteration in mitochondrial respiratory chain complexes was described by network analyses.
Haemolysis and oxidative stress are peculiar features in pulmonary hypertension and endothelial 
 dysfunction23–27. Glutathione, a major non-protein thiol in living organisms, plays a central role in coordinat-
ing the body’s antioxidant defence  processes28–30. Perturbation of glutathione status of a biological system has 
been reported to lead to serious consequences. In the present study, low level of GSH in CTEPH dysfunctional 
ECs was observed. Interestingly quantitative proteomics analysis showed a down-regulation of GPX4 and GPX1 
proteins that catalyse the formation of glutathione disulphide in presence of hydrogen peroxide (Table 1). GPX1 
decreased the bioavailability of NO and increased the oxidative  stress31. Therefore, the underlying mechanisms 
might be attributed to the unavailability of GSH, the substrate for GPX. The capacity of the glutathione system 
to deal with free radicals mainly depends upon the activity of peroxidase and glutathione reductase (GR). Glu-
tathione reductase keeps a high ratio of GSH/GSSG in normal cells. In CTEPH-ECs glutathione reductase might 
be in lower levels, which in turn is linked to the decreased concentration of GPx and reduced glutathione. The 
down regulation of identified GPX4, GPX1, NOS3 proteins attested the increment of oxidative stress. Among 
Figure 2.  Molecules involved in cell movement significantly altered in CTEPH patients (last version IPA, 
QIAGEN Inc., https ://www.qiage nbioi nform atics .com/produ cts/ingen uityp athwa y-analy sis), in red the 
increased genes, in green those decreased. The color intensity is positive related to the up- or down-gene’s 
regulation; orange line leads to activation, yellow lines for findings inconsistent with state of downstream 
molecule; grey line for effect not predicted.
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these GPX4 found as one of the most down-regulated protein. Under physiological conditions, the antioxidants 
related to glutathione peroxidase family proteins GPX1 and GPX4 protects the cells from oxidative  stress32. GPX4 
prevents the cells from ferroptosis, a non-apoptotic cell death as consequence of iron-dependent accumulation 
of lipid reactive oxygen species (ROS)33. Elevated levels of GPX1 protected the cultured HPAECs from hydrogen 
peroxide induced cell  death34. Reduced expression of GPX1 can also lead to inflammatory activation of ECs, 
that further increase to a proatherogenic endothelial  phenotype35. Genetic deletion of GPX1 decreased bioavail-
ability of NO and increased the oxidative  stress35. Moreover, normal ECs always generate endothelial nitric oxide 
synthase (eNOS), which is essential to maintain various endothelial functions including the vascular smooth 
Figure 3.  Canonical Pathways that are differentially regulated in CTEPH patients versus controls, in orange the 
up regulated (z score > 0) and in blue the down regulated ones (zscore < 0) (last version IPA, QIAGEN Inc., https 
://www.qiage nbioi nform atics .com/produ cts/ingen uityp athwa y-analy sis).
Figure 4.  Pathways involved in mitochondrial dysfunction significantly altered in CTEPH patients ((last 
version IPA, QIAGEN Inc., https ://www.qiage nbioi nform atics .com/produ cts/ingen uityp athwa y-analy sis), in 
red the increased genes, in green those decreased. The color intensity is positive related to the up- or down-
gene’s regulation; orange line leads to activation, yellow lines for findings inconsistent with state of downstream 
molecule; grey line for effect not predicted.
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Figure 5.  Molecules involved in Metabolism of reactive oxygen species significantly altered in CTEPH patients 
(IPA), in red the increased genes, in green those decreased.
Figure 6.  Levels of oxidants and antioxidants in dysfunctional ECs of CTEPH. Data were shown in 
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muscle relaxation, vascular endothelial growth factor (VEGF) induced angiogenesis, suppression of inflamma-
tory cell migration and adhesion, angiogenesis, inhibition of thrombosis and coagulation. The impairment of 
eNOS causes the endothelial dysfunction and oxidative stress which further increases the atherogenesis. The 
endothelial NOS3 protein, responsible to produce NO, was found down regulated and vascular endothelium 
glycoprotein ENG, involved in the negative regulation of NO production, was found up regulated. Therefore, 
the reduction in NO bioavailability, resulting from reduced NO production and/or increased NO degradation 
by superoxide anion, describes the onset of endothelial  dysfunction27.
Moreover, NADPH oxidase-derived ROS play a role in vascular pathology as well as in the maintenance of 
normal physiological vascular  function36. NADPH has been suggested to act as an indirectly operating antioxi-
dant, thus maintaining the antioxidative power of  glutathione37. In the present study, lower level of NADPH was 
observed in CTEPH, suggesting the increasing of oxidative stress in dysfunctional ECs.
The increased levels of AOPPs might explain the involvement of higher global inflammatory activity in 
endothelial  dysfunction38. Increased AOPPs production might be involved in the generation of various types 
of  ROS39. The accumulation of ROS has been well established in the pathogenesis of several diseases including 
 diabetes40,  atherosclerosis41, renal  ischemia42, inflammatory  diseases43 and  cancer44. Increased production of ROS 
in dysfunctional ECs might enhance pro-inflammatory pathways and affect protein, lipid and enzymatic activity.
In summary, the mechanisms underlying endothelial dysfunction implicates the alterations in metabolism, 
inflammation and oxidative stress events.
Conclusions
This is the first study to attempt the description of molecular network in in endothelial dysfunction associated 
with CTEPH using patient-derived pathological ECs. Quantitative proteomic profiling in endothelial dysfunc-
tion reveals the differentially regulated proteins that might behave as a biomarker signature of vascular injury, 
metabolism and oxidative stress. Increased production of oxidants and decreased production of antioxidant 
biomarkers as well as down regulation of protein which had an antioxidant property strongly explained the cor-
relation of the role of oxidative stress in endothelial dysfunction of CTEPH.
In conclusion the study unveiled the pathophysiological mechanisms and some important functional modules, 
constituted by differentially regulated proteins, dysregulated during the disease.
Potential limitations and future perspective of the study. Although we used a statistically signifi-
cant number of patients-derived ECs to identify underlying mechanisms associated with endothelial dysfunc-
tion of CTEPH, further experiments need to be performed to validate the expression of proteins using clinical 
samples e.g. blood, for determining them as a potential prognostic marker for early prediction of endothelial 
dysfunction. Despite knowing the background of patients from whom we have collected specimens to isolate 
ECs, the long-term medical history and potential risk factors to which they might have exposed is anonymous. 
The perspective of the current study would be to perform more experiments to unveil mechanistic and func-
tional characteristics of PLOD2 and ENG1, which might provide an in-depth understanding of endothelial 
dysfunction. To understand the effect of these dysregulated proteins in downstream signaling pathways, gene 
overexpression and knockdown analysis will be performed in vitro. Additionally, to understand whether the 
upregulation of PLOD2 and ENG1 might play a key role in inducing oxidative stress, we will use various bio-
chemical and molecular biology approaches followed by gene overexpression in ECs. To further overcome the 
limitations of the current study, perspective studies would be performed using patient-specific induced pluripo-
tent stem cell-derived endothelial cells (iPSC-ECs).
Materials and methods
Endothelial cell culture. Commercially available human pulmonary artery endothelial cells (HPAE) were 
used as controls. Five individual ECs lines, derived from surgical specimens obtained in patients with CTEPH 
(CTEPH-ECs) who underwent pulmonary endarterectomy, were received from Dr. Olga Tura, Research Sci-
entist, Department of Pulmonary Medicine, Hospital Clínic-Institut d’Investigacions Biomèdiques August Pi 
iSunyer (IDIBAPS), University of Barcelona, Spain. The study was conducted in accordance with the Declaration 
of Helsinki, was approved by the Committee on Human Research of our institution and all subjects gave written 
informed consent (Comité Ético de Investigación Clínica del Hospital Clínic de Barcelona). The clinical charac-
teristics of CTEPH endothelial cells are summarized in Supplementary Table 4.
The specimens containing thromboembolic material with clear thrombus were obtained after pulmonary 
endarterectomy (PEA) surgery from CTEPH patients at IDIBAPS. Material were washed with PBS and minced 
into 1–2 mm pieces. Explants were seeded into 0.2% gelatin-coated 6-well plates and maintained under standard 
cell culture conditions. After 24 h, tissue explants, non-adherent cells, and debris were aspirated. Medium was 
changed every other day until the first passage of pulmonary endothelial outgrowth cells emerged and cells were 
cultured as previously  described45.
Protein extraction and In‑solution trypsin digestion. Confluent cells were trypsinized and collected 
by centrifugation at 1200 rpm for 5 min. Harvested cells were washed two times with cold PBS. The cell pel-
lets were resuspended in the solubilization buffer (8 M urea in 50 mM Tris–HCl, 30 mM NaCl, pH 8.5 and 1% 
protease inhibitor) and incubated on ice for 5–10 min. Cell lysates were further homogenized by sonication in 
an ice bath for three times each for 5 s with 30 s intervals, using an ultra sonicator. Samples were centrifuged at 
14,000 rpm for 20 min at 4ºC. The protein supernatant was collected into the new Eppendorf tube and pelleted 
cell debris was discarded. Samples were stored at -80 ºC until we use it for further experiments. The protein 
estimation was carried out by using the Bradford assay.
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10 µg of total protein was resuspended in 50 mM ammonium bicarbonate. Reduction was carried out by 
incubating 5 mM final concentration of DTT for 30 min at 52 °C, followed by an alkylation with 15 mM final 
concentration of iodoacetamide for 20 min in the dark at room temperature. Trypsin digestion was allowed 
at 37 °C overnight, with an enzyme: substrate ratio of 1:10. The resulting peptides were used for MS analysis.
Mass spectrometry and data analyses. Tryptic peptides were analyzed using a Dionex Ultimate 3000 
nano-LC system (Sunnyvale CA, USA) connected to an Orbitrap Fusion Tribrid Mass Spectrometer (Thermo 
Scientific, Bremen, Germany) equipped with a nano-electrospray ion source. Peptide mixtures were pre-concen-
trated onto an Acclaim PepMap 100 – 100 µm × 2 cm C18 and separated on EASY-Spray column, 15 cm × 75 µm 
ID packed with Thermo Scientific Acclaim PepMap RSLC C18, 3 µm, 100 Å. The temperature was setting to 
35 °C and the flow rate was 300 nL/min. Mobile phases were the following: 0.1% Formic acid (FA) in water 
(solvent A); 0.1% FA in water/acetonitrile (solvent B) with 2/8 ratio. Peptides were eluted from the column with 
the following gradient: 4% to 28% of B for 90 min and then 28% to 40% of B in 10 min, and to 95% within the 
following 6 min to rinse the column. Column was re-equilibrated for 20 min. Total run time was 130 min. One 
blank was run between triplicates to prevent sample carryover. MS spectra were collected over an m/z range of 
375–1500 at 120,000 resolutions, operating in the data dependent mode, cycle time of 3 s. Higher-energy col-
lisional dissociation (HCD) was performed with collision energy set at 35%. Each sample was analysed in three 
technical  triplicates45.
Resulting MS raw files from all the technical and biological replicates were analysed by using MaxQuant 
 software48 (version 1.6.2.3). Andromeda search engine was used to identify MS/MS based peptide and proteins 
in MaxQuant comprises a target-decoy approach with less than 1% of False Discovery Rate (FDR). In the pre-
sent study we used Uniprot_Homosapiens database. Trypsin was used for enzyme specificity, 2 missed cleavages 
and maximum five number of modifications per peptide was allowed. Methionine oxidation and acetylation (N 
terminus) was used as a variable modification. Carbamidomethylation was used as a fixed modification. The 
proteins were selected with a minimum of two peptides. For the label-free quantification of proteins, we applied 
MaxLFQ algorithm. Match between the runs option was enabled and remaining default parameters were permit-
ted. Data available on request from the authors.
An open source Perseus  software46 (version 1.6.1.3; Max Planck Institute of Biochemistry, Germany) was 
used for the identification of statistically significantly differentially regulated proteins. The interpretation and 
visualization of results obtained from MaxQuant software were performed by a two-sample t-test using Perseus 
(v1.6.1.3, Max Planck Institute of Biochemistry, Germany). Statistical parameters (p < 0.05; q < 0.05, q = FDR 
adjusted p-value) were set to identify the differentially expressed proteins between samples, categorized in two 
groups: CTEPH-EC (patients) and HPAEC (controls) (log2 ratio). Variabilities of biological replicates were 
measured with Pearson correlation coefficient values of the LFQ intensities. The differentially regulated proteins 
with a minimum of two peptides and FDR adjusted p-value < 0.05 were considered as statistically  significant46.
Protein network analysis. The network protein analysis related to significantly altered proteins was car-
ried out by IngenuityPathwaysAnalysis(IPA)(QIAGENInc., https ://www.qiage nbioi nform atics .com/produ cts/
ingen uityp athwa y-analy sis). The statistical enrichment of involved pathways is performed by the right-tailed 
Fisher’s exact test, in correlation with QIAGEN Knowledge Base, assigning a p-value. The core analyses per-
formed by IPA, using the differentially expressed proteins in the uploaded dataset, assess signaling pathways, 
molecular interaction network and biological functions that are likely to be perturbed. The overall activation/
inhibition states of canonical pathways are predicted based on a z-score algorithm. This z-score is used to sta-
tistically compare the uploaded dataset with the pathway patterns. The pathways are colored to indicate their 
activation z-scores: orange predict a gain of function, while blue a loss of function. The pathway is activated 
when molecules’ causal relationships with each other (i.e., activation edge and the inhibition edge between the 
molecules based on literature findings) generate an activity pattern for the molecules and the end-point func-
tions in the pathway.
Quantitative gene expression analysis. Total RNA extraction and conversion to first-strand cDNA 
were done using iScript RT-qPCR sample preparation reagent (Bio-Rad) and Maxima First Strand cDNA Syn-
thesis Kit (Thermo Scientific), respectively according to the manufacturer’s protocol. Quantitative RT-PCR anal-
ysis was performed using an ABI PRISM 7000 Sequence detection system cDNA was amplified in triplicate using 
Maxima SYBR Green/ROX qPCR Master Mix (Thermo Scientific). The thermal cycling programme started at 
95 °C for 10 min for enzyme activation, followed by 40 cycles of amplification at 95 °C for 15 s, followed by 60 °C 
for 1 min. Gene expression was normalized to the housekeeping gene RPLP0. Relative expression of targeted 
genes was determined using the  2-ΔΔCT method. P value below 0.05 were considered as statistically significant.
Biomolecular assays. Advanced oxidation protein product (AOPP) levels were analysed by using the 
OxiSelect AOPP kit (STA318, Cell Biolabs, San Diego, CA, USA) following the manufacturer’s protocol. Briefly, 
the confluent cells were collected, lysed in buffer (150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% 
SDS, 50 mM Tris, pH 8, 5 mM EDTA and protease inhibitors) and centrifuged for 20 min at 14,000 rpm. The 
pellet containing cell debris was discarded; the protein supernatant was collected and quantified by Bradford 
assay. 50 µg of protein in 200 µL final volume of control and pathological cell lysates were subjected to10 µL of 
chloramine reaction initiator followed by 20 µL of stop solution. Absorbance was recorded at 340 nm by using 
the spectrophotometric plate reader (PowerWave biotek). Cell lysates used in this assay was prepared from the 
ECs in passages between 6–9. Experiments were performed with biological and technical  replicates47.
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Protein carbonyl content, a general indicator of protein oxidation was measured fluorometrically (480 nm 
excitation/530 nm emission) using a commercial kit (Cell Biolabs, OxiSelect No. STA-307) as per the instructions 
provided by the manufacturer. Experiments were performed with biological and technical replicates.
ROS was measured by OxiSelect ROS Assay Kit (Cell Biolabs, STA-342) as per the manufacturer protocol. 
Briefly, the control and pathological ECs were grown in 96 well plate at a density of 9 ×  103 cells and incubated 
with the dichloro-dihydro-fluorescein diacetate (DCFH-DA) containing medium at 37 °C for 60 min in the 
dark. The confluent cells were lysed, and the fluorescence was recorded by using the fluorometric plate reader at 
480 nm/530 nm. Experiments were performed with biological and technical replicates.
GSH/GSSG ratio in control and pathological EC cultures was determined using GSH/GSSG Ratio Detec-
tion Assay Kit (Fluorometric-Green) (Abcam Inc. #ab138881) according to the manufacturer’s guidelines. The 
samples were prepared by lysis of total cell protein in 0.5% NP-40 lysis buffer followed by a dilution of 1:50 for 
GSH analysis. In brief, serial dilution of GSH and GSSG stock standards were prepared along with assay mixtures 
for detection of GSH and total GSH using 100 × Thiol green stock solutions, assay buffer and GSSG probe. A 
one- step fluorometric reaction of sample with respective assay buffers were incubated for 30 min. Fluorescence 
intensity was then monitored at Ex/Em of 490/520 nm. GSSG was determined by subtracting GSH from total 
GSH. Finally, the ratio of GSH was plotted against GSSG to obtain the GSH  activity48. Experiments were per-
formed with biological and technical replicates.
NADPH/NADP ratio in control and pathological ECs was determined by using NADP/NADPH quantification 
kit (Sigma) as per the manufacturer’s protocols. Briefly, 1 ×  106 confluent cells were pelleted and washed with cold 
PBS. Cells were extracted with 800 µl of NADP/NADPH extraction buffer and allowed to incubation for 10 min 
on ice. Samples were centrifuged at 10,000g for 10 min and supernatant used for determining the ratio of NADP 
and NADPH. To remove the enzymes that may consume NADPH rapidly were removed by filtering through a 
10kDA cut-off spin filter (Millipore, UFC501096). An aliquot of the supernatant was heated at 60 °C for 30 min 
to decompose the  NADP+, cooled on ice, and spun quickly to remove the precipitate. Another aliquot of the 
supernatant was not heated. Both aliquots were reacted with  NADP+ cycling buffer and enzyme mix (containing 
glucose-6-phosphate dehydrogenase (G6PDH) for 5 min at room temperature to convert  NADP+ to NADPH. 
The solutions were then incubated with NADPH developer for 2 h and the absorbance measured at 450 nm. The 
amount of NADPH (heated sample) and the total  NADP+ and NADPH (unheated sample) were quantified from 
an NADPH standard  curve49. Experiments were performed with biological and technical replicates.
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